Why Rigetti Computing Stock Keeps Going Up

The U.S. Department of Commerce confirmed grants under the CHIPS and Science Act, with Rigetti Computing set to receive up to $100 million for quantum miniaturization and cryostat research. The funding could extend Rigetti’s cash runway by about 15 months, but the company is still burning more than $80 million annually, limiting the long-term impact. Rigetti shares have already surged 63% in three trading days on the announcement and related reports.

Analysis

The market is treating the announcement like non-dilutive funding, but the more important effect is validation of the sector’s industrial policy bid: the government is not just subsidizing R&D, it is explicitly trying to create a domestic supply chain for quantum hardware. That tends to favor the companies closest to infrastructure and manufacturing scale more than the pure-play science experiments, because procurement, integration, and follow-on contracts usually accrue to the least-fragile balance sheets.

For RGTI, the grant is a runway extension, not a business model breakthrough. A 15-month cash bridge matters only if it meaningfully improves technical milestones or unlocks commercial partnerships before the market re-rates the next financing round; otherwise the stock is simply trading on a longer-duration option premium. The second-order risk is that the award becomes a ceiling on valuation rather than a floor: when speculative rallies collide with a still-burning cash profile, upside can exhaust quickly once investors start anchoring on dilution probability again.

IBM looks like the cleaner beneficiary because it can absorb the award inside a broader quantum roadmap without changing its financing profile, while GFS gets a more subtle benefit: any government-backed push to domesticate quantum hardware increases the strategic value of U.S.-based advanced manufacturing capacity. The underappreciated loser is not another quantum name, but later-stage private competitors that now have to compete against a subsidized cohort with lower cost of capital and political signaling behind it. That can compress partnership economics across the ecosystem over the next 6-18 months.

Consensus is likely overestimating the permanence of this move. The catalyst is binary and front-loaded, but the fundamental test is whether awarded capital produces measurable progress in error rates, packaging, and cryogenic integration within two to four quarters; if not, today’s gap-up risks retracing hard as the narrative shifts back to execution and financing. The cleanest trade is to fade the most extended pure-play while respecting that the government program may keep the group elevated for months, not days.

Key Decisions for Investors

• Fade the post-news move in RGTI via a partial short or put spread over 1-3 months; thesis is that the award extends runway but does not remove dilution risk, so upside should compress once the market re-prices financing reality.
• Prefer long IBM over RGTI for 3-6 months as the lower-risk beneficiary: the grant adds optionality without balance-sheet dependence, making IBM the cleaner way to express quantum exposure with limited downside from a failed commercialization cycle.
• Add GFS on weakness as a relative winner from industrial policy spillover; the trade works if domestic fabrication and cryogenic supply-chain buildout attracts follow-on spending, with a 6-12 month horizon.
• Pair trade: long IBM / short RGTI to isolate subsidy-backed durability versus speculative extension; risk/reward improves if near-term enthusiasm fades but sector sentiment remains constructive.
• If maintaining RGTI exposure, use call spreads instead of equity for the next 30-60 days; this keeps upside participation while capping damage if the market pivots back to cash burn and dilution concerns.